not require further analgesia. Nausea or vomiting was a presenting feature of pancreatitis in 11 patients treated with pethidine and 15 with buprenorphine. This settled after analgesia in six and seven patients respectively. Only one patient receiving buprenorphine developed vomiting after administration of the drug. Specific questioning did not elicit any other side effects. Duration of pain relief (h)
Comnparisont of median pain scores before and after injection of pethidine and buprenorphine
Pethidine9 5 9 2
Comment
This study shows that pethidine and buprenorphine provide comparable analgesia in acute pancreatitis. Although pethidine has some cost advantage ovet buprenorphine, it is a controlled and potentially addictive opiate. Potential addiction to narcotics in young adults presenting with recurrent episodes of pancreatitis, often secondary to alcohol abuse, is a cause for concern among clinicians treating this disease. Buprenorphine appears to have little potential for physical dependence; and may be preferred in such patients. Potential objections to buprenorphine include its side effects of vomiting, dizziness, and respiratory depression, which are only partially reversed by naloxone. Respiratory depression was not seen in this study, but anxiety that it may occur may prevent the routine use of buprenorphine in acute pancreatitis, particularly in elderly patients with severe disease. Downing Case 4-A 19 year old Nigerian secondary school student of upper middle class had spent all his life in the metropolitan city of Lagos. Four months before admission he had been diagnosed as suffering from lichen planus, which regressed with topical and systemic corticosteroids. One month later rapidly progressive and generalised nodular skin lesions erupted and he became bedridden. Examination on admission showed nodular violaceous skin lesions and generalised adenopathy without enlarged viscera. Radiographically there was reticulonodular shadowing in both lung fields but no evidence of skeletal lesions. Skin biopsy showed lesions similar to those of mycosis fungoides. The white cell count was 62 x 109/l and 10°, of the cells were abnormal, resembling the tumour cell bone marrow infiltrate. Cell surfaces of a skin nodule and bone marrow lymphocytes were typed as mature T, consistent with a diagnosis of adult T cell leukaemia. Doxorubicin hydrochloride 60 mg/IM2 was given. When last seen at six month follow up he was well.
Case 8-This patient was a 57 year old Nigerian petty trader of lower socioeconomic class. On presentation she gave a three month history of progressive weight loss and abdominal swelling. She was moderately emaciated and had generalised adenopathy and an enlarged liver and spleen. Serum calcium concentration measured on a single occasion was normal.
Clinically she had chronic lymphocytic leukaemia. She defaulted from follow up after beginning chlorambucil and is believed to have died three months later.
These two Nigerian patients had antibodies against HTLV and the clinical features of HTLV associated leukaemia-lymphoma. In one case we documented a T cell phenotype similar to that in other cases of the virus associated sentinel disease adult T cell leukaemia.3
Thus typical cases of adult T cell leukaemia have now been documented from Japan, the West Indies, South America, in blacks from the southern United States, and, with this report, for the first time in black Africans.3
In our case 1 the patient had skin lesions consistent with cutaneous T cell lymphoma and was HTLV seronegative. This observation confirms that of reports that typical cutaneous T cell lymphoma is only rarely associated with HTLV infection. Ater treatment (min) After exercise (min)
The effect of placebo and terfenadine on the mean baseline FEV1 (SEM) and mean percentage falls in FEVI after exercise in 10 patients with asthma.
The mean baseline values of FEV, (SEM) before treatments on four days of testing were: 3-16 (0-26) 1, 3-20 (0-26) 1, 3-08 (0.28) 1, and 3 09 (0-23) 1 and no statistical difference was noted. Although terfenadine produced a small bronchodilator effect this did not reach statistical significance with any of the doses used. After exercise the mean maximal percentage falls in FEV, (SEM) after placebo and terfenadine 60 mg, 120 mg, and 180 mg were 32-9 (4-8)%, 27-6 (5 0)%, 22-8 (4-1)%, and 21-2 (4-6)% respectively 10 minutes after exercise (see figure) . Terfenadine at 120 mg (p<0.02) and 180 mg (p<0.01) offered significant protection compared with placebo. There was considerable variation in response to terfenadine between patients: three patients had good protection, four showed partial protection, and in three terfenadine had no effect at any of the doses. The non-responders were all over the age of 40. The only side effect observed was dryness of mouth. None of the patients complained of drowsiness or tiredness.
Terfenadine given orally in a single dose of 120 mg and 180 mg offered significant protection against exetcise induced asthma in the patients studied, whereas 60 mg of terfenadine showed no significant inhibition. Terfenadine is a potent antagonist of histamine H, receptor mediated responses both in vitro and in vivo and does not possess anticholinergic, antiserotonin, or antiadrenergic properties. It antagonises histamine in two ways: by competitive blockade at low concentrations and by a non-equilibrium blockade at higher con-
